Home LiteratureArticle Details
PMID: 19366445 Published · epublish English

Survival in Norwegian BRCA1 mutation carriers with breast cancer.

Hereditary cancer in clinical practice ·Vol. 7 ·No. 1 ·2009-12-29

Hagen Anne Irene, Tretli Steinar, Maehle Lovise, Apold Jaran, Vedå Nina, Møller Pål

Abstract

Several studies of survival in women with BRCA1 mutations have shown either reduced survival or no difference compared to controls. Programmes for early detection and treatment of inherited breast cancer, have failed to demonstrate a significant improvement in survival in BRCA1 mutation carriers.One hundred and sixty-seven women with disease-associated germline BRCA1 mutations and breast cancer from 1980 to 2001 were identified. Tumour characteristics, treatment given and survival were recorded. A control group comprising three hundred and four women matched for age, time of diagnosis and stage were used to compare survival.BRCA1 mutation carriers were found to have a poorer prognosis, which could be explained by neither the mode of surgical treatment nor the use of adjuvant chemotherapy. BRCA1 mutation carriers with node negative breast cancer had worse overall survival than controls.Our findings confirm the serious prognosis of BRCA1-associated breast cancer even when diagnosed at an early stage, and that type of treatment does not influence prognosis.

Article Info
Journal
Hereditary cancer in clinical practice
Abbr.
Hered Cancer Clin Pract
Published
2009-12-29
Indexed
2009-05-06
Updated
2010-09-27
Language
English
Country/Region
Poland
NLM ID
101231179
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com